| 37.65 Delayed Data As of 4:00pm ET |  +0.30 / +0.80%Today’s Change | 33.50 Today|||52-Week Range 111.36 | -36.96% Year-to-Date |
| Nektar (NKTR) Catches Eye: Stock Jumps 8.7% Nov 13 / Zacks.com - Paid Partner Content | Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates Nov 07 / Zacks.com - Paid Partner Content |
| Nektar (NKTR) Q3 Earnings & Sales Beat Estimates, Shares Up Nov 08 / Zacks.com - Paid Partner Content | What's in the Cards for Nektar (NKTR) This Earnings Season? Nov 05 / Zacks.com - Paid Partner Content |
| Previous close | 37.35 |
| Today’s open | 37.43 |
| Day’s range | 37.01 - 38.54 |
| Volume | 3,094,426 |
| Average volume (3 months) | 2,257,568 |
| Market cap | $6.5B |
| Earnings growth (last year) | +43.64% |
| Earnings growth (this year) | +726.77% |
| Earnings growth (next 5 years) | -7.38% |
| Revenue growth (last year) | +86.00% |
| P/E ratio | 9.1 |
| Price/Sales | 30.27 |
| Price/Book | 67.84 |
| Today’s change | Today’s % change | |
|---|---|---|
| BLUEbluebird bio Inc | -3.79 | -3.15% |
| TECHBio-Techne Corp | -0.55 | -0.34% |
| EXASExact Sciences Corp | -0.96 | -1.38% |
| NBIXNeurocrine Bioscienc... | -13.37 | -13.44% |
| Next reporting date | February 28, 2019 |
| EPS forecast (this quarter) | -$0.63 |
| Annual revenue (last year) | $307.7M |
| Annual profit (last year) | -$96.7M |
| Net profit margin | -31.42% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Howard W. Robin |
Chief Operating Officer & Senior Vice President John Nicholson |
Corporate headquarters San Francisco, California |
